ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Gene Editing

Editas and Celgene expand CRISPR cell-therapy deal

by Ryan Cross
November 17, 2019 | APPEARED IN VOLUME 97, ISSUE 45

 

Editas Medicine, a CRISPR gene-editing company, will receive a $70 million payment from Celgene to develop T-cell therapies for cancer and autoimmune diseases. The deal updates a narrower collaboration that Editas struck with Juno Therapeutics in 2015 focused exclusively on cancer. Celgene acquired Juno, a CAR T-cell therapy company, in 2018. The new deal also allows Editas to work on natural killer cells.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment